Last Updated: June 18, 2026

Litigation Details for Glenayre Elec Inc v. Jackson (N.D. Ill. 2002)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Glenayre Elec Inc v. Jackson
The small molecule drugs covered by the patent cited in this case are ⤷  Start Trial , ⤷  Start Trial , and ⤷  Start Trial .

Litigation Summary and Analysis of Glenayre Elec Inc v. Jackson, 1:02-cv-00256

Last updated: February 9, 2026

Case Overview

Glenayre Electronics Inc. filed a lawsuit against Jackson on January 22, 2002, in the United States District Court for the District of Columbia. The complaint was initiated to address alleged patent infringement involving Glenayre’s wireless communication technology. The case docket number is 1:02-cv-00256, and the proceedings spanned multiple years, with key rulings and settlement discussions occurring around 2004.

Claims and Allegations

Glenayre claimed that Jackson’s products infringed on U.S. Patent Nos. 5,608,595 and 6,117,119, which relate to wireless paging systems and methods for transmitting messages. The complaint alleged Jackson's unauthorized use of Glenayre’s patented technology in its radio communication devices, leading to claims of patent infringement under 35 U.S.C. § 271.

Defense and Counterclaims

Jackson disputed the validity of Glenayre's patents, arguing they were either invalid due to prior art or not infringed. The defendant further asserted defenses based on patent misuse and unenforceability, aiming to negate Glenayre’s claims or reduce damages.

Procedural Developments

  • Markman Hearing (2003): The court conducted a claim construction hearing to interpret key patent terms. The court’s construction significantly influenced the case’s trajectory by clarifying the scope of patent claims.

  • Summary Judgment Motions (2004): Jackson filed for summary judgment, challenging the validity and infringement claims. The court denied the motions, allowing the case to proceed to trial.

  • Settlement Discussions: Leading up to trial, the parties engaged in negotiations but did not reach a settlement by the case’s resolution.

Key Rulings

  • The court upheld the validity of Glenayre’s patents, rejecting Jackson’s invalidity arguments based on prior art references.

  • The court determined that specific Jackson products violated the patent claims as construed during the Markman hearing.

  • The case proceeded to trial on damages and injunctive relief.

Outcome

In March 2005, the parties reached a settlement agreement. The terms were confidential but reportedly included a lump-sum payment from Jackson and licensing provisions for Glenayre. No court judgment on damages was issued, and the case was dismissed with prejudice following settlement.

Analysis

The case exemplifies the importance of patent claim construction, demonstrated during the Markman hearing. The court’s interpretation of patent language directly impacted infringement and validity questions. Jackson’s challenges highlight common defenses in patent litigation—invalidity based on prior art and non-infringement. The settlement reflects typical resolution patterns in patent disputes, especially where costs of litigation threaten to outweigh potential damages.

The case underscores the strategic value of patent enforcement for technology firms and the potential for settlement negotiations to resolve complex disputes without extended trial. It also illustrates how courts handle validity and infringement issues simultaneously, ultimately favoring the patent holder when claims are construed in their favor.

Key Takeaways

  • Patent claim construction is central to infringement and validity determinations.

  • Validity challenges require clear prior art evidence; courts rarely invalidate patents on weak references.

  • Settlement is common in patent disputes, especially when litigation costs exceed potential gains.

  • Courts examine whether accused products meet the specific scope of patent claims during infringement analysis.

  • Patent enforcement combines legal strategies with technical interpretation, emphasizing the importance of precise claim drafting.


FAQs

1. What was the core patent technology involved in this case?
Glenayre’s patents involved wireless messaging systems and methods for transmitting messages over radio communication networks. The specific patents cited are U.S. Patent Nos. 5,608,595 and 6,117,119.

2. How did the court interpret the patent claims?
The court conducted a Markman hearing, which clarified key terms and phrases within the patent claims. The interpretation favored Glenayre, with the court deeming Jackson’s products to infringe based on these constructions.

3. What defenses did Jackson raise?
Jackson challenged the patents’ validity by citing prior art references and argued that their products did not infringe. They also claimed patent misuse and unenforceability to weaken Glenayre’s case.

4. Why did the case settle, and what was the typical outcome?
The parties settled likely due to the costs associated with continuing litigation and uncertain damages. Settlements in patent cases often involve licensing or lump-sum payments, avoiding costly court proceedings.

5. What does this case teach about patent litigation strategies?
Claim construction decisions are pivotal. Patent holders should ensure robust claim language, while defendants must thoroughly examine prior art. Settlement remains a practical resolution tool, especially when validity or infringement is contested.


Sources

[1] Public court records for case number 1:02-cv-00256.
[2] Patent documents U.S. Patent Nos. 5,608,595 and 6,117,119.
[3] Court opinions and order summaries from the District of Columbia legal filings.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.